Asset
ABATACEPT
Bristol-Myers Squibb Company Common Stock
Revenue
| Period | Revenue |
|---|---|
| Q2 2026 | $1.0B |
| Q1 2026 | $818.0M |
| Q4 2025 | $1.0B |
| Q3 2025 | $964.0M |
| Q2 2025 | $963.0M |
| Q1 2025 | $770.0M |
| Q4 2024 | $1.0B |
| Q3 2024 | $936.0M |
| Q2 2024 | $948.0M |
| Q1 2024 | $798.0M |
| Q4 2023 | $985.0M |
| Q3 2023 | $925.0M |
| Q2 2023 | $927.0M |
| Q1 2023 | $764.0M |
| Q4 2022 | $913.0M |
| Q3 2022 | $883.0M |
| Q2 2022 | $876.0M |
| Q1 2022 | $792.0M |
| Q4 2021 | $864.0M |
| Q3 2021 | $870.0M |
| Q2 2021 | $814.0M |
| Q1 2021 | $758.0M |
| Q4 2020 | $867.0M |
| Q3 2020 | $826.0M |
| Q2 2020 | $750.0M |
| Q1 2020 | $714.0M |
| Q4 2019 | $792.0M |
| Q3 2019 | $767.0M |
| Q2 2019 | $778.0M |
| Q1 2019 | $640.0M |
| Q4 2018 | $731.0M |
| Q3 2018 | $675.0M |
| Q2 2018 | $711.0M |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.
Clinical trials (52)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00048568 | phase3 | completed | 2002-12-01 | 2009-10-01 | Bristol-Myers Squibb | A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate |
| NCT00484289 | phase3 | completed | 2006-12-01 | 2010-12-01 | Bristol-Myers Squibb | A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis |
| NCT00409838 | phase3 | completed | 2007-04-01 | 2008-07-01 | Bristol-Myers Squibb | A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate |
| NCT00420199 | phase3 | completed | 2007-05-01 | 2009-08-01 | Bristol-Myers Squibb | A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate |
| NCT00767325 | phase3 | completed | 2008-12-01 | 2011-10-01 | Bristol-Myers Squibb | A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography |
FDA applications (1)
| Application | Approved | Type | Applicant |
|---|---|---|---|
| BLA 125118 | 2005-12-23 | BLA | Bristol-Myers Squibb Company |
Marketed products (5)
- ORENCIA
- Orencia
- Orencia
- Orencia
- Orencia